跳至主要内容
临床试验/NCT01321749
NCT01321749已完成1 期

The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease

Capital Medical University2 个研究点 分布在 1 个国家目标入组 196 人开始时间: 2008年1月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
196
试验地点
2
主要终点
Blood Pressure and Heart Rates;

研究概览

简要总结

This study is a prospective, randomized, single-center trial, designed to observe the effect of remote limb ischemic preconditioning on ischemic cerebral vascular disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with stroke or transient ischemic attack (TIA) within 180 days and the neurologic deficits were well matched to the territory of the stenosed artery, with intracranial arterial stenosis of at least 50% by angiography, at least 70% by ultrasound, or at least 70% by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA)
  • Age between 18 to 80 years old
  • Trial of Org 10172 in Acute Stroke Treatment-1 (TOAST-1) subtype
  • National Institutes of Health Stroke Scale (NIHSS) score 0-15, and Modified Rankin Scale (mRS) score 0-
  • ABCD2 score between 6 to 7
  • Stable vital signs, normal hepatic and renal functions,
  • No hemorrhagic tendencies.

排除标准

  • Within 72 hrs of intra-artery or intravenous thrombolysis
  • Intracranial hemorrhage or large area of cerebral infarction (more than 1/3 middle cerebral artery perfusion territory)
  • Any soft tissue, orthopedic, or vascular injury, wounds or fractures in extremities which may pose a contraindication for application of the preconditioning cuffs
  • Acute myocardial infarction
  • Systolic blood pressure more than 200 mmHg after drug control
  • Peripheral blood vessel disease
  • Hematologic disease
  • Severe hepatic and renal dysfunction
  • Severe or unstable concomitant disease
  • Cannot tolerate BLIPC or without informed consent
  • Patients who did not complete the whole treatment procedure.

结局指标

主要结局

Blood Pressure and Heart Rates;

时间窗: at the time points of baseline and 1, 15 and 30 days after BLIPC treatment

Plasma Biomarkers of Coagulation and Fibrinolysis

时间窗: the time points of baseline and 1, 15 and 30 days after BLIPC treatment

blood samples were collected one hour after every times of BLIPC procedure ended, and assayed with the immuno-turbidimetry assay on the coagulation laboratory autoanalyzer

Number of Patients Who Got New Brain Lesions

时间窗: 300 days after treatment

We compared the number of patients who got new lesions in the Diffusion-weighted magnetic resonance imaging (DWI-MRI)

次要结局

  • The Time Point Until the First Stroke Recurrence,(At the 300-day after the initial treatment)
  • Brain Perfusion Improvement Are Evaluated With SPECT and TCD(300-day after treatment)

研究者

发起方
Capital Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ji Xunming

Xuan Wu Hospital

Capital Medical University

研究点 (2)

Loading locations...

相似试验